- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07553819
가정 기반 호흡 근육 훈련 및 유산소 운동 프로그램이 현 흡연자와 과거 흡연자의 폐 건강을 개선하는 방법
호흡근 훈련과 유산소 운동이 흡연자의 폐 건강에 미치는 영향: 폐암 예방을 위한 파일럿 병렬 그룹 연구
This clinical trial studies whether home-based respiratory muscle training (RMT) and aerobic exercise (AE) programs can be used to improve lung health in current and former cigarette smokers. Lung cancer, the leading cause of cancer death, is overwhelmingly caused by exposure to cigarette smoke. Research suggests that daily activity reduces lung cancer risk in current and former smokers. However, current and former smokers are generally not active and new approaches to improve lung health are needed. During the home-based RMT program, participants use a handheld device to complete breathing exercise sessions consisting of breathing in and out against adjustable resistance. During the home-based AE program, participants complete aerobic exercises using a stationary bike working at a moderate workload against adjustable resistance. The home-based RMT and AE programs may be effective ways to strengthen the breathing muscles, which may improve lung health in current and former cigarette smokers.
연구 개요
상태
정황
상세 설명
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of delivering a home-based AE and RMT program in individuals at high risk for lung cancer.
II. Assess the effects of AE and RMT on patient-reported outcomes (PROs), including QoL, fatigue, dyspnea, performance metrics such as respiratory muscle strength and lower extremity strength; the 6-minute walk test; and daily activity levels in high-risk individuals.
III. Investigate whether RMT and/or AE improve peripheral and exhaled biomarkers associated with lung injury, inflammation, and/or oxidative stress.
OUTLINE: Participants scheduled for a computed tomography (CT) scan are assigned to cohort A, participants who call the New York State Quitline (NYSQL) are assigned to cohort B.
COHORT A: Participants are randomized to 1 of 3 arms.
ARM I: Participants complete RMT sessions via the Power Lung device over 20-30 minutes each consisting of three sets of 15 breaths at a gradual increase in resistance, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call once a week (QW) to provide support, enhance safety, and promote training compliance on study.
ARM II: Participants complete tailored intensity AE cycling sessions progressing to over 30 minutes each, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study.
ARM III: Participants receive education on AE and RMT including recommendations aligned with current guidelines 5 days a week for 12 weeks.
COHORT B: Participants are randomized to 1 of 2 arms.
ARM IV: Participants complete RMT sessions as in arm I for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study.
ARM V: Participants receive education on AE and RMT as in arm III on study.
Additionally, all patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.
After completion of study intervention, participants may be optionally followed up at week 24.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New York
-
Buffalo, New York, 미국, 14263
- Roswell Park Cancer Institute
-
연락하다:
- Andrew D. Ray
- 전화번호: 716-845-2381
- 이메일: Andrew.Ray@RoswellPark.org
-
수석 연구원:
- Andrew D. Ray
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 50 years old
- Current smoker with a ≥ 20-pack-years history
- Former smoker within the past 15 years, with a history of ≥ 20 pack-years (CT scan cohort only)
- Participant must be able to speak, read and comprehend English language
- Cognitively capable of following direction and performing the intervention
- Understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- Any previous lung cancer diagnoses and or undergoing treatment for any cancer
- Recent pneumonia, bronchitis, or other inflammatory conditions in the lungs, including but limited to chronic obstructive pulmonary disease (COPD) and/or asthma exacerbation within the previous 6 months
- Have uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort A Arm I (RMT)
Participants complete RMT sessions via the Power Lung device over 20-30 minutes each consisting of three sets of 15 breaths at a gradual increase in resistance, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study. |
Ancillary studies Ancillary studies Ancillary studies
다른 이름들:
Ancillary studies Undergo blood, nasal swab, exhaled breath, and urine sample collection
다른 이름들:
Complete RMT sessions
다른 이름들:
Receive virtually supervised session/call
다른 이름들:
|
|
실험적: Cohort A Arm II (AE)
Participants complete tailored intensity AE cycling sessions progressing to over 30 minutes each, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study. |
Ancillary studies Ancillary studies Ancillary studies
다른 이름들:
Ancillary studies Undergo blood, nasal swab, exhaled breath, and urine sample collection
다른 이름들:
Receive virtually supervised session/call
다른 이름들:
Complete tailored intensity AE cycling sessions
다른 이름들:
|
|
활성 비교기: Cohort A Arm III (AE and RMT education)
Participants receive education on AE and RMT including recommendations aligned with current guidelines 5 days a week for 12 weeks. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study. |
Ancillary studies Ancillary studies Ancillary studies
다른 이름들:
Ancillary studies Undergo blood, nasal swab, exhaled breath, and urine sample collection
다른 이름들:
Receive AE and RMT education
다른 이름들:
|
|
실험적: Cohort B Arm IV (RMT)
Participants complete RMT sessions as in arm I for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study. |
Ancillary studies Ancillary studies
다른 이름들:
Ancillary studies Undergo blood, nasal swab, exhaled breath, and urine sample collection
다른 이름들:
Complete RMT sessions
다른 이름들:
Receive virtually supervised session/call
다른 이름들:
|
|
활성 비교기: Cohort B Arm V (AE and RMT education)
Participants receive education on AE and RMT as in arm III on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study. |
Ancillary studies Ancillary studies
다른 이름들:
Ancillary studies Undergo blood, nasal swab, exhaled breath, and urine sample collection
다른 이름들:
Receive AE and RMT education
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Compliance rate (Feasibility)
기간: Up to 12 weeks
|
The primary objective is in the feasibility of conducting the respiratory muscle training (RMT) and aerobic exercise (AE) intervention relative to the sham control. In the RMT group, overall compliance (e.g., compliant at all time points) will be estimated using 90% confidence intervals (CIs) obtained Clopper-Pearson method. The lower bounds will define a plausible lower limit for true (unobserved) compliance rates. Additionally, compliance status will be modeled as a function of time (e.g., week), and pre-specified exogenous factors using a generalized estimating equation logistic regression model (autoregressive covariance structure). Estimates of compliance rates will be obtained by time-point and tests about the appropriate contrasts of model estimates will be used to determine if there is a time trend. |
Up to 12 weeks
|
|
Adherence rate (Feasibility)
기간: Up to 12 weeks
|
The primary objective is in the feasibility of conducting the RMT and AE intervention relative to the sham control. In the RMT group, overall adherence (complete ≥ 70% of sessions) rates will be estimated using 90% CIs obtained Clopper-Pearson method. The lower bounds will define a plausible lower limit for true (unobserved) adherence rates. |
Up to 12 weeks
|
|
Assessing inspiratory and expiratory muscle strength
기간: At baseline, 6 weeks, and 12 weeks
|
Participants will complete 3 sets of 15 breaths, 5 days/week using commercially available Power Lung. resistance will be increased 5-10% every week . Participants will rate and log their effort |
At baseline, 6 weeks, and 12 weeks
|
|
change in St. George Respiratory Questionnaire (SGRQ)
기간: At baseline, 6 weeks, and 12 weeks
|
The SGRQ comprises of 50 items and consists of two parts. Scores range from 0-100, with higher scores indicating worse quality of life. |
At baseline, 6 weeks, and 12 weeks
|
|
Functional capacity
기간: At baseline, 6 weeks, and 12 weeks
|
Measured by the 6-Minute Walk Test. Will be summarized at pre-, 6-week and post-intervention timepoints, regardless of treatment regimen, using the appropriate descriptive statistics and graphically summarized. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. Comparisons at the 6-week and 3-month follow-up visits will be secondary and will only be performed if the primary comparison for the corresponding endpoint reaches statistical significance. For cohort A, Bonferroni's correction will be applied to adjust for three pairwise comparisons. |
At baseline, 6 weeks, and 12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lower extremity strength
기간: At baseline and 12 weeks
|
Measured using the 30-Second Sit-to-Stand Test. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. |
At baseline and 12 weeks
|
|
Physical performance
기간: At baseline and 12 weeks
|
Measured using the Short Physical Performance Battery. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. |
At baseline and 12 weeks
|
|
Physical activity levels
기간: Up to 12 weeks
|
daily step counts and minutes at various intensity levels will be monitored with an activity tracker. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. |
Up to 12 weeks
|
|
Patient-reported outcomes on Fatigue
기간: At baseline and 12 weeks
|
he Functional Assessment of Chronic Illness Therapy (FACIT- fatigue scale) is a 13-item patient-reported measure of fatigue. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52. The higher the score, the lower the score the greater the fatigue severity |
At baseline and 12 weeks
|
|
High-sensitivity C-reactive protein
기간: At baseline and 12 weeks
|
The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. |
At baseline and 12 weeks
|
|
Cardiac biomarkers
기간: At baseline and at 12 weeks
|
Will assess cardiac biomarkers, such as high-sensitivity troponin T and N-terminal pro-brain natriuretic peptide. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. Biomarker data will be appropriately transformed prior to analysis to meet model assumptions. |
At baseline and at 12 weeks
|
|
Dyspnea patient reported response
기간: Baseline and at 12 weeks
|
he Dyspnea-12 describes the different qualitative dimensions of breathlessness. Each 12- item (seven for the physical and five for the affective components) score ranges from 'none' (score 0) to 'severe' (score 3) with a total score ranging from 0 to 36 (lower is better), a physical score ranging from 0 to 21 and an affective score ranging from 0 to 15 |
Baseline and at 12 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Andrew D Ray, Roswell Park Cancer Institute
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 호흡기 질환
- 폐 질환
- 호흡기 신생물
- 흉부 신생물
- 폐 신생물
- 운동 활동
- 움직임
- 근골격계 생리 학적 현상
- 근골격계 및 신경 생리적 현상
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 마인드 바디 요법
- 보완 요법
- 운동 기법
- 물리 치료 양식
- 환자 치료
- 건강 서비스
- 의료 시설 인력 및 서비스
- 아동 건강 서비스
- 지역 사회 보건 서비스
- 예방 보건 서비스
- 사회 경제적 요인
- 인구 특성
- 진단 기술, 호흡기 시스템
- 진단 기술, 심혈관
- 심장 기능 테스트
- 호흡기 기능 테스트
- 에르고메트리
- 운동
- 행동 양식
- 완화 치료
- 조기 개입, 교육
- 교육 상태
- 시편 처리
- 호흡 운동
- 운동 테스트
- 가속도계
기타 연구 ID 번호
- I-4565025
- I-4565025 (기타 식별자: Roswell Park Cancer Institute)
- NCI-2026-01887 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .